Trial Profile
Study assessing PD-1 ligand, CD8+ T-cells as predictive biomarkers for response in patients with metastatic clear cell renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Atezolizumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 20 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium